ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "ImmunoGen, Inc." (IMGN) Report Updated: Aug 22, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"ImmunoGen, Inc." (IMGN)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology
Competitors: SPHS,EXEL,DMPI,MNOV

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: F down no change
Last Week: F same no change
Two Weeks Ago: F up no change
service keys

"ImmunoGen, Inc."© quotemedia

Company Profile

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugates technology. It offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. The company’s clinical stage anticancer compounds include IMGN853 for the treatment of ovarian cancer, endometrial cancer, and other cancers, as well as IMGN529 and coltuximab ravtansine for the treatment of diffuse large B-cell lymphoma and other B-cell malignancies; and preclinical stage compounds comprise IMGN779 for the treatment of acute myeloid leukemia and myelodysplastic syndrome. It also develops BT-062 for multiple myeloma; BAY 94-9343 for mesothelioma and ovarian cancers; SAR650984 that is in Phase II clinical trials for multiple myeloma; AMG 595, which is in Phase I clinical trials for glioblastoma; and SAR566658 Phase I clinical trials for CA6-positive solid tumors. In addition, the company develops AMG 172 that is in Phase I clinical trials for clear cell renal cell carcinoma; SAR408701, which is in Phase I clinical trials for CEACAM5-positive solid tumors; LOP628 that is in Phase I clinical trial for c-Kit-positive cancers; and PCA062, which is in Phase I clinical trial for P-cadherin-positive cancers. ImmunoGen, Inc. has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; Sanofi; Merck; and Takeda, as well as research agreement with CytomX Therapeutics to develop probody-drug conjugates against a specified number of cancers. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.